Treatment of Ischemic Heart Disease in Hypotension and Bradycardia

Managing ischemic heart disease becomes significantly more complex when the patient also has hypotension and bradycardia. These haemodynamic conditions constrain the choice of antianginal therapy, since several standard agents interact directly with heart rate and blood pressure.

Clinical situation

European and American guidelines recognise that hypotension and bradycardia can prevent adequate use of beta-blockers, calcium channel blockers, and nitrates. When angina symptoms are not well-controlled, or when these first-choice agents cannot be tolerated due to haemodynamic constraints, an alternative approach carries a Class IIa guideline recommendation.

Approach

The protocol for this scenario targets an antianginal agent specifically chosen because it does not affect heart rate or blood pressure — making it viable when haemodynamic intolerance rules out standard options. The complete regimen, dosing, and selection criteria are contained in the full structured protocol.

Treatment goals

Reduction in the frequency of angina attacks and in the use of sublingual nitrates.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/suaa060

The guidelines suggest it if the symptoms are not well-controlled with BB, calcium channel blockers, or nitrates or if hypotension and bradycardia limit the use of these drugs (Class IIa indication of European and American guidelines).

The most recently introduced drugs, ranolazine and ivabradine, have not been shown to modify the patients' prognosis and their adoption in clinical practice has been anything but disruptive, however, they are an important resource in hypotensive and bradycardic patients.

This drug does not affect heart rate or blood pressure.

In the treated group a reduction in the frequency of angina attacks and a reduction in the use of sublingual nitrates was highlighted.

View source ↗